Launched last spring, a Phase 1 clinical trial studying the safety and initial effectiveness of the immunotherapy drug nivolumab with and without stereotactic radiosurgery is continuing to enroll patients, now at two locations.
This chordoma-specific clinical trial, which opened last year at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, is now enrolling patients at a second trial site, Memorial Sloan Kettering Cancer Center in New York. The trial offers a promising new therapeutic option to chordoma patients over the age of 15 whose tumors have come back in the same area or have spread to other parts of the body.
Nivolumab is a type of drug called a checkpoint inhibitor, which enables immune cells to recognize and destroy cancer cells. Combined with A type of external beam radiation that uses special equipment to position a patient and precisely deliver radiation to tumors in or near the brain, over a small number of treatments., which is thought to make tumors more visible to the immune system, researchers believe that these therapies together will harness the immune system to more effectively fight chordoma.
The Foundation is proud to have supported this trial with a $344,000 research grant made possible by the generosity of many in the chordoma community. It builds upon laboratory research that we have supported at Johns Hopkins since 2011, which found that the combination of a checkpoint inhibitor and radiation could have strong activity against chordomas in mice.
- For more information about the study, eligibility requirements and answers to frequently asked questions, visit the trial information page on our website.
- Full eligibility requirements can also be found on clinicaltrials.gov.
- A Chordoma Foundation Patient Navigator is also available to help answer any other questions you may have.
|The Chordoma Foundation maintains a Clinical Trials Catalogue on our website which lists all chordoma-specific trials, as well as all other trials deemed relevant to chordoma patients by our MAB (it currently includes 17 trials worldwide).|